[Identification of patients with axial spondylarthritis in primary care (AWARE study)].

Identifikation von Patienten mit axialer Spondyloarthritis in der Primärversorgung (AWARE-Studie).

Journal

Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162

Informations de publication

Date de publication:
Aug 2019
Historique:
entrez: 4 8 2019
pubmed: 4 8 2019
medline: 8 10 2019
Statut: ppublish

Résumé

Early detection of patients with axial spondylarthritis (axSpA) in primary care is difficult. The combination of various parameters indicative of inflammatory back pain (AWARE criteria) was found to be beneficial in an initial study. Review of the criteria for the identification of young patients with axSpA and chronic back pain (≥3 months of back pain). In adult patients with chronic back pain and age at onset of symptoms <45 years, orthopedic surgeons documented various possible axSpA characteristics before referral to the rheumatologist. Overall, the data from 1306 patients were recorded. Of these, ultimately 500 patients were also seen by rheumatologists, 199 patients (39.8%) were diagnosed with axSpA while 301 (60.2%) had non-specific back pain. A total of 87 patients had ankylosing spondylitis (44%) and 112 non-radiographic axSpA (56%). The ASAS classification criteria were fulfilled by 226 patients (45.2%). The mean age of axSpA patients was 38 years, 56% were male with a mean duration of back pain of 98 months. The AWARE criteria had a sensitivity and specificity of 69.3% and 40.3% (n = 343), respectively, when ≥4/5 criteria were chosen. Positive imaging for sacroiliitis using magnetic resonance imaging (MRI) or X‑ray was present in 77% of patients and positive HLA-B27 was identified in 59% of axSpA patients. The combination of positive imaging and HLA-B27 had the highest likelihood ratio for diagnosis of axSpA. Although the study design used here led to a preselection and thus to a bias in the statistical evaluation, the study confirmed the benefit of the AWARE criteria for the early detection of patients with axSpA. In further studies, the 2‑stage approach with initially 3 clinical questions and then an optional HLA-B27 test is currently being investigated further.

Sections du résumé

BACKGROUND BACKGROUND
Early detection of patients with axial spondylarthritis (axSpA) in primary care is difficult. The combination of various parameters indicative of inflammatory back pain (AWARE criteria) was found to be beneficial in an initial study.
OBJECTIVE OBJECTIVE
Review of the criteria for the identification of young patients with axSpA and chronic back pain (≥3 months of back pain).
MATERIAL AND METHODS METHODS
In adult patients with chronic back pain and age at onset of symptoms <45 years, orthopedic surgeons documented various possible axSpA characteristics before referral to the rheumatologist.
RESULTS RESULTS
Overall, the data from 1306 patients were recorded. Of these, ultimately 500 patients were also seen by rheumatologists, 199 patients (39.8%) were diagnosed with axSpA while 301 (60.2%) had non-specific back pain. A total of 87 patients had ankylosing spondylitis (44%) and 112 non-radiographic axSpA (56%). The ASAS classification criteria were fulfilled by 226 patients (45.2%). The mean age of axSpA patients was 38 years, 56% were male with a mean duration of back pain of 98 months. The AWARE criteria had a sensitivity and specificity of 69.3% and 40.3% (n = 343), respectively, when ≥4/5 criteria were chosen. Positive imaging for sacroiliitis using magnetic resonance imaging (MRI) or X‑ray was present in 77% of patients and positive HLA-B27 was identified in 59% of axSpA patients. The combination of positive imaging and HLA-B27 had the highest likelihood ratio for diagnosis of axSpA.
CONCLUSION CONCLUSIONS
Although the study design used here led to a preselection and thus to a bias in the statistical evaluation, the study confirmed the benefit of the AWARE criteria for the early detection of patients with axSpA. In further studies, the 2‑stage approach with initially 3 clinical questions and then an optional HLA-B27 test is currently being investigated further.

Identifiants

pubmed: 31375960
doi: 10.1007/s00393-018-0550-2
pii: 10.1007/s00393-018-0550-2
doi:

Substances chimiques

HLA-B27 Antigen 0

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

568-576

Références

Rheumatology (Oxford). 2017 Jan;56(1):95-102
pubmed: 27997346
Ann Rheum Dis. 2015 Dec;74(12):e69
pubmed: 26483254
Ann Rheum Dis. 2013 Oct;72(10):1621-7
pubmed: 23065731
Ann Rheum Dis. 2003 Jun;62(6):519-25
pubmed: 12759287
J Rheumatol. 2015 Jan;42(1):31-8
pubmed: 25399389
Lancet. 2007 Apr 21;369(9570):1379-1390
pubmed: 17448825
Z Rheumatol. 2017 Apr;76(3):195-207
pubmed: 28364218
Rheumatology (Oxford). 2009 Jul;48(7):812-6
pubmed: 19447774
Arthritis Rheum. 2009 Mar;60(3):717-27
pubmed: 19248087
Ann Rheum Dis. 2015 Aug;74(8):1483-7
pubmed: 25990288
Ann Rheum Dis. 2018 Jan;77(1):63-69
pubmed: 28939631
Rheumatology (Oxford). 2016 Jan;55(1):56-65
pubmed: 26275972
Rheumatology (Oxford). 2013 Aug;52(8):1418-24
pubmed: 23559574
Nat Rev Rheumatol. 2017 May;13(5):264-266
pubmed: 28298649
Lancet. 2017 Jul 1;390(10089):73-84
pubmed: 28110981
Ann Rheum Dis. 2011 Oct;70(10):1782-7
pubmed: 21821621
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Arthritis Rheum. 2009 Apr;60(4):946-54
pubmed: 19333933
Rev Rhum Engl Ed. 1995 Jan;62(1):10-5
pubmed: 7788318
J Rheumatol. 2011 Nov;38(11):2452-60
pubmed: 21921100
Arthritis Rheum. 1984 Apr;27(4):361-8
pubmed: 6231933
Z Rheumatol. 2016 May;75(4):346-53
pubmed: 27142379
Ann Rheum Dis. 2013 Oct;72(10):1646-53
pubmed: 23139266
Ann Rheum Dis. 2017 Jun;76(6):1086-1092
pubmed: 28062405
Ann Rheum Dis. 2016 May;75(5):791-4
pubmed: 26768406
Ann Rheum Dis. 2010 Jul;69(7):1264-8
pubmed: 20566619
Arthritis Rheumatol. 2018 Jul;70(7):1042-1048
pubmed: 29513924
Ann Rheum Dis. 2015 Dec;74(12):e68
pubmed: 26416898
Ann Rheum Dis. 2016 Nov;75(11):1958-1963
pubmed: 26768408
Ann Rheum Dis. 2018 May;77(5):699-705
pubmed: 29343510
Ann Rheum Dis. 2017 Jun;76(6):978-991
pubmed: 28087505

Auteurs

J Braun (J)

Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. j.braun@rheumazentrum-ruhrgebiet.de.
Ruhr Universität Bochum, Bochum, Deutschland. j.braun@rheumazentrum-ruhrgebiet.de.

T Mosch (T)

Medical Affairs, AbbVie Deutschland GmbH & Co KG, Wiesbaden, Deutschland.

I Fischer (I)

Biostatistik-Tübingen, Tübingen, Deutschland.

U Kiltz (U)

Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland.
Ruhr Universität Bochum, Bochum, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH